Moderna coronavirus vaccine shows 'promising' safety and immune response results in published Phase 1 study, but more research is needed

Posted at 5:34 PM, Jul 15, 2020
and last updated 2020-07-15 17:34:08-04

(WXYZ) — A leading vaccine candidate for COVID-19 has shown that it can safely produce a “rapid and strong" immune response in humans. That’s according to the developer, biotech company Moderna whose interim phase 1 study results were published in the New England Journal of Medicine.

This is good news, and yes, Moderna says that neutralizing antibodies were observed in 100% of its evaluated participants.

Remember, the body's immune system fights off infections by producing antibodies. They’re called neutralizing antibodies because when they find the virus, they bind to it. They basically grab a hold of it to neutralize and disable it.

Now, all 45 participants in the stage 1 trial not only produced neutralizing antibodies, but their levels were very similar to people who had caught the virus and recovered from COVID-19. So this sounds very promising.

Overall, there were mild side effects like pain at the injection site. All of the participants were given two shots, about a month apart. And the more common effects after the second shot were fatigue and chills, with 80% of the volunteers experiencing those symptoms.

Also, 60% developed a headache and 53% had muscle pain. But all of these symptoms didn’t last very long. And it’s not uncommon to experience these types of side effects when it comes to vaccinations in general.

When it comes to the clinical development of new vaccines, there is a three-phase process. Phase 1 focuses on a small number of participants. The goal is to check how safe the vaccine is and see if it does what it’s developed to do.

Phase 2 expands the number of participants and has a longer time length than Phase 1.

Lastly, phase 3 involves thousands of people and that’s when a vaccine is really evaluated to see just how effective and safe it is.

Now Moderna is expected to begin phase 3 in just a couple of weeks with 30,000 participants at 87 locations across the US. It will be a placebo-controlled study. So one group will get the vaccine, and another group will get injected with a placebo.

Everyone will be followed for two years.

Moderna hopes to have some strong data from their phase 3 trial concerning their vaccine’s safety and effectiveness by the end of the year. If all goes well, it could be made available to high-risk populations under the FDA’s Emergency Use Authorization. And Moderna says it’s still on track to produce about 500 million doses per year, with the possibility of manufacturing 1 billion doses per year beginning in 2021.

Additional Coronavirus information and resources:

Click here for a page with resources including a COVID-19 overview from the CDC, details on cases in Michigan, a timeline of Governor Gretchen Whitmer's orders since the outbreak, coronavirus' impact on Southeast Michigan, and links to more information from the Michigan Department of Health and Human Services, the CDC and the WHO.

View a global coronavirus tracker with data from Johns Hopkins University.

See complete coverage on our Coronavirus Continuing Coverage page.

Visit our The Rebound Detroit, a place where we are working to help people impacted financially from the coronavirus. We have all the information on everything available to help you through this crisis and how to access it.